High Free Cash Flow Stocks
HLN is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
HALEON PLC-ADR (HLN) Stock Price & Overview
NYSE:HLN • US4055521003
Current stock price
9.93 USD
-0.04 (-0.4%)
At close:
9.93 USD
0 (0%)
After Hours:
The current stock price of HLN is 9.93 USD. Today HLN is down by -0.4%. In the past month the price decreased by -3.87%. In the past year, price increased by 0.4%.
HLN Key Statistics
52-Week Range8.71 - 11.42
Current HLN stock price positioned within its 52-week range.
1-Month Range9.645 - 10.635
Current HLN stock price positioned within its 1-month range.
- Market Cap
- 44.227B
- P/E
- 20.69
- Fwd P/E
- 17.66
- EPS (TTM)
- 0.48
- Dividend Yield
- 1.94%
HLN Stock Performance
Today
-0.4%
1 Week
+1.85%
1 Month
-3.87%
3 Months
-0.70%
Longer-term
6 Months +10.95%
1 Year +0.40%
2 Years +16.41%
3 Years +11.95%
5 Years N/A
10 Years N/A
HLN Stock Chart
HLN Stock Screens
HLN currently appears in the following ChartMill screener lists.
HLN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HLN. When comparing the yearly performance of all stocks, HLN is a bad performer in the overall market: 63.58% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
HLN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to HLN. While HLN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
HLN Earnings
Next Earnings DateApr 29, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported2.751B
EPS Surprise %
Revenue Surprise -3.78%
HLN Forecast & Estimates
25 analysts have analysed HLN and the average price target is 11.91 USD. This implies a price increase of 19.98% is expected in the next year compared to the current price of 9.93.
For the next year, analysts expect an EPS growth of 6.33% and a revenue growth -1.37% for HLN
Analysts
Analysts80
Price Target11.91 (19.94%)
EPS Next Y6.33%
Revenue Next Year-1.37%
HLN Groups
Sector & Classification
HLN Financial Highlights
Over the last trailing twelve months HLN reported a non-GAAP Earnings per Share(EPS) of 0.48. The EPS increased by 6.59% compared to the year before.
Income Statements
Revenue(TTM)11.23B
Net Income(TTM)1.67B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.11% | ||
| ROA | 5.11% | ||
| ROE | 10.15% | ||
| Debt/Equity | 0.47 |
Chartmill High Growth Momentum
EPS Q2Q%280.16%
Sales Q2Q%-0.29%
EPS 1Y (TTM)6.59%
Revenue 1Y (TTM)-0.61%
HLN Ownership
Ownership
Inst Owners60.22%
Shares4.45B
Float4.45B
Ins Owners0.06%
Short Float %0.37%
Short Ratio1.92
HLN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HLN
Company Profile
Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
Company Info
IPO: 2022-07-18
HALEON PLC-ADR
Building 5, First Floor, The Heights
Weybridge SURREY GB
Employees: 24000
Phone: 441932822000
HALEON PLC-ADR / HLN FAQ
Can you describe the business of HALEON PLC-ADR?
Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
What is the stock price of HALEON PLC-ADR today?
The current stock price of HLN is 9.93 USD. The price decreased by -0.4% in the last trading session.
What is the dividend status of HALEON PLC-ADR?
HALEON PLC-ADR (HLN) has a dividend yield of 1.94%. The yearly dividend amount is currently 0.18.
How is the ChartMill rating for HALEON PLC-ADR?
HLN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for HLN stock?
The PE ratio for HALEON PLC-ADR (HLN) is 20.69. This is based on the reported non-GAAP earnings per share of 0.48 and the current share price of 9.93 USD.
Can you provide the number of employees for HALEON PLC-ADR?
HALEON PLC-ADR (HLN) currently has 24000 employees.
Can you provide the short interest for HLN stock?
The outstanding short interest for HALEON PLC-ADR (HLN) is 0.37% of its float.